Previously we showed that the activator protein-1 site and the runt domain binding site in the collagenase-3 promoter act cooperatively in response to parathyroid hormone (PTH) in the rat osteoblastic osteosarcoma cell line, UMR 106-01. Our results of the expression pattern of core binding factor ␣1 (Cbfa1), which binds to the runt domain site, indicated that there is no change in the levels of Cbfa1 protein or RNA under either control conditions or after PTH treatment. The importance of posttranslational modification of Cbfa1 in the signaling pathway for PTH-induced collagenase-3 promoter activity was analyzed. PTH stimulation of collagenase-3 promoter activity was completely abrogated by protein kinase A (PKA) inhibition. To determine the role of PKA activity with respect to Cbfa1 activation (in addition to its known activity of phosphorylating cAMP-response element-binding protein to enhance c-fos promoter activity), we utilized the heterologous Gal4 transcription system. PTH stimulated the transactivation of activation domain-3 in Cbfa1 through the PKA site. In vitro phosphorylation studies indicated that the PKA site in the wild type activation domain-3 is a substrate for phosphorylation by PKA. Thus, we demonstrate that PTH induces a PKA-dependent transactivation of Cbfa1, and this transactivation is required for collagenase-3 promoter activity in UMR cells.
Previously we showed that the activator protein-1 site and the runt domain binding site in the collagenase-3 promoter act cooperatively in response to parathyroid hormone (PTH) in the rat osteoblastic osteosarcoma cell line, UMR 106-01. Our results of the expression pattern of core binding factor ␣1 (Cbfa1), which binds to the runt domain site, indicated that there is no change in the levels of Cbfa1 protein or RNA under either control conditions or after PTH treatment. The importance of posttranslational modification of Cbfa1 in the signaling pathway for PTH-induced collagenase-3 promoter activity was analyzed. PTH stimulation of collagenase-3 promoter activity was completely abrogated by protein kinase A (PKA) inhibition. To determine the role of PKA activity with respect to Cbfa1 activation (in addition to its known activity of phosphorylating cAMP-response element-binding protein to enhance c-fos promoter activity), we utilized the heterologous Gal4 transcription system. PTH stimulated the transactivation of activation domain-3 in Cbfa1 through the PKA site. In vitro phosphorylation studies indicated that the PKA site in the wild type activation domain-3 is a substrate for phosphorylation by PKA. Thus, we demonstrate that PTH induces a PKA-dependent transactivation of Cbfa1, and this transactivation is required for collagenase-3 promoter activity in UMR cells.
The predominant targets of parathyroid hormone (PTH) 1 are the skeleton and kidney. PTH binds to PTH/PTH-related protein receptors present on the plasma membrane of osteoblasts (1) and induces the expression of genes such as collagenase-3 (matrix metalloproteinase-13) (2), interleukin-6, leukemia inhibitory factor (3), insulin-like growth factor-I (4), and prostaglandin G/H synthase-2 (5). Collagenase-3 is able to degrade types I, II, III, and IV collagen, the cartilage proteoglycan, aggrecan, and other components of the extracellular matrix (6 -8) . Apparently due to its ability to degrade a wide range of matrix components, its physiological expression is limited to situations in which rapid and effective remodeling of collagenous extracellular matrices is required, i.e. fetal bone development and postnatal bone remodeling in both rodents (9, 10) and humans (11, 12) . By mutating the cleavage site for collagenase in type I collagen, it has also been shown that this enzyme has a critical role in mediating PTH-induced osteoclastic bone resorption in vivo (13) .
Collagenase-3 is strongly induced by bone resorbing agents such as PTH in the rat osteoblastic osteosarcoma cell line, UMR 106-01 (2, 14) . Previously we have identified the activator protein-1 (AP-1) and runt domain (RD) binding sites as necessary for PTH-induced collagenase-3 promoter activity. We have also demonstrated that there is increased binding of c-Fos and c-Jun proteins to the AP-1 site in response to PTH, whereas there is no change in the abundance of Cbfa (AML)-related proteins binding to the RD binding site (15) . Cbfa is a mammalian homolog of the Drosophila genes runt (16) and lozenge (17) . Bone-specific genes such as osteocalcin and osteopontin (major noncollagenous components of the bone matrix) contain Cbfa consensus sites, referred to as the polyomavirus enhancer-binding protein-2␣A/osteoblast specific element-2/nuclear matrix protein-2 site (18 -20) .
Cbfa1 is essential for the maturation of osteoblasts, and targeted disruption of the cbfa1 gene in mice produced skeletal defects (21, 22) that are essentially identical to those found in human cleidocranial dysplasia. A recent study shows that the mutant mice do not express collagenase-3 during fetal development, indicating that collagenase-3 is one of the target genes regulated by Cbfa1 (23) . Cbfa1 is also involved in osteoclastogenesis through regulation of osteoclast differentiation factor/ osteoprotegerin ligand in osteoblast lineage cells (24) . Cbfa1 is a key transcription factor in bone cells, and the activity of runt proteins is required for completion of osteoblast differentiation (25, 26) . Cbfa1 is regulated by signaling through ␣2-integrin (27) . The expression of Cbfa1 is also controlled by Smad2, an essential intracellular component for the signal transduction of transforming growth factor-␤ in osteoblastic cells (28) . Earlier, we demonstrated that only the level of c-Fos and c-Jun, not Cbfa1, is increased by PTH, and even in the presence of c-Fos, c-Jun, and Cbfa1, collagenase-3 promoter activity is strongly increased by PTH treatment (15) . These results suggest that a posttranslational modification of Cbfa1 may be required for PTH induction of the collagenase-3 gene through Cbfa1 activity. To understand the Cbfa1 regulation in PTH-induced collagenase-3 promoter activity, we analyzed its expression by Western blot and Northern blot analyses. We dissected the signaling pathway involved for PTH-induced collagenase-3 promoter activity using ERK, PKC, and PKA inhibitors. Further-more, the posttranslational modification of Cbfa1 was determined using the heterologous Gal4 transcription system. Cbfa1 was shown to be phosphorylated in vitro by PKA. Our results provide evidence of PKA-dependent Cbfa1 transactivation, specifically as required for PTH-induced collagenase-3 promoter activity in UMR cells.
EXPERIMENTAL PROCEDURES
Materials-Parathyroid hormone (rat 1-34) was purchased from Sigma. Restriction endonucleases were products of New England BioLabs, Inc., Beverly, MA, and radionuclides were obtained from NEN Life Science Products. Synthetic oligonucleotides were synthesized by Life Technologies, Inc. Tissue culture media and reagents were obtained from the Washington University Tissue Culture Center, St. Louis, MO. Fetal bovine serum was a product of JRH Biosciences, Lenexa, KS and was also purchased through Washington University. All other chemicals were obtained from Sigma or Fisher.
Western Blot-UMR 106-01 cells were cultured as described previously (15) . Cell lysates containing 50 g of total protein in lysis buffer were electrophoresed by 12% SDS-PAGE. The proteins were transferred electrophoretically to polyvinylidene difluoride membrane (BioRad). After blocking in Tween-Tris-buffered saline (0.1% Tween 20, 138 mM NaCl, 5 mM KCl, and 25 mM Tris-HCl (pH 8.0)) containing 5% (w/v) nonfat dry milk, the membrane was probed with affinity-purified antiCbfa1 antibody (diluted 1:1000) (anti-human AML-3, kindly provided by Dr. Scott Hiebert) followed by incubation with horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (diluted 1:5000). The antigen-antibody complexes were detected by ECL (Amersham Pharmacia Biotech).
Northern Blot-Poly(A) ϩ RNA from control and PTH-treated UMR cells was isolated using the FastTrack kit (InVitrogen). Poly(A) ϩ RNA (1 g/lane) was electrophoresed on a 1% agarose, 2.2 M formaldehyde gel in MOPS buffer (40 mM MOPS (pH 7.0), 10 mM sodium acetate, and 1 mM EDTA). RNA was transferred to Zeta-Probe GT-membrane (BioRad) and hybridized in 50% formamide, 5X SSC, 10X Denhardts, 0.1% SDS, 50 mM Na 3 PO 4 , and 100 g/ml salmon sperm DNA at 42°C. Antisense RNA and cDNA probes used for hybridization were labeled with riboprobe and random priming kits (Promega), respectively. A mouse Cbfa1 (Osf2/Cbfa1)-specific cDNA was kindly provided by Dr. Gerard Karsenty.
DNA Transfection-Earlier we characterized the rat collagenase-3 promoter and identified the region conferring maximal PTH responsiveness to within 148 base pairs upstream from the transcription start site and the collagenase-3 promoter construct (Ϫ148 C'ase-3) contains both the AP-1 and RD sites (15) . The wild type Gal4 AD3 construct, containing the activation domain-3 (AD3) in the proline-, serine-, threoninerich domain region of mouse Osf2/Cbfa1 (29) was obtained by ligating the appropriate coding sequence (amino acids 241 to 374) downstream and in-frame with a sequence coding for the DNA binding domain of the yeast transcription factor Gal4 (amino acids 1 to 147) in the vector pFA-CMV (Stratagene). The PKA mutant of AD3 construct (serine residue 347 changed to alanine in PKA consensus phosphorylation site) was created by Quick Change site-directed mutagenesis kit (Stratagene). These constructs were verified by sequencing using the Sequenase kit (Amersham Pharmacia Biotech) and tested for their ability to transactivate a luciferase reporter gene driven by five copies of the Gal4 upstream activation sequence and the adenovirus E1b minimal promoter in pFR-Luc (Stratagene).
UMR cells were seeded in 6-well plates (2 ϫ 10 5 cells/well) and transiently transfected with either 100 ng of collagenase-3 promoter construct containing CAT as a reporter gene or 50 ng of Gal4 construct and 50 ng of reporter luciferase plasmid or the amounts of DNA indicated in the figures using LipofectAMINE as recommended by the manufacturer (Life Technologies, Inc.). PTH treatment was performed the following day either for 24 h for CAT reporter gene transfection or 6 h for luciferase reporter gene transfection. CAT activity was measured in duplicate after the addition of 25 or 50 l of cell lysate to a 100-l reaction volume consisting of final concentrations of 250 M n-butyryl-coenzyme A and 23 mM [
14 C]chloramphenicol (0.125 Ci/assay). Twenty l of cell lysate was used for measuring luciferase activity with a luminometer, Optocomp II, using the luciferase assay system (Promega). All experiments were repeated three times.
In Vitro Phosphorylation-The recombinant wild type and PKA mutant AD3 proteins were expressed from the pET30 vector in Escherichia coli BL21 cells (Novagen). When the optical density (600 nm) of the expression culture reached 0.4 -0.6, expression of the protein was induced by the addition of 0.1 mM isopropyl-␤-D-thiogalactoside. After 5 h of induction, the cells were harvested. The histidine-tagged protein was purified by His⅐Bind resin as recommended by the manufacturer (Novagen). The recombinant proteins also contained S-tag. The recombinant protein (2 g) was incubated in a final volume of 20 l containing 20 mM Tris (pH 7.4), 10 mM MgCl 2 , 50 M ATP, 5 Ci of [ 32 P]ATP, and purified PKA catalytic subunit (Promega). The reaction was carried out at 37°C for 15 min and stopped by the addition of SDS-PAGE loading buffer. The samples were separated by SDS-PAGE and blotted onto polyvinylidene difluoride membrane. The membrane was first exposed to autoradiography and then analyzed by Western blot using horseradish peroxidase-conjugated anti-S-tag protein as recommended by the manufacturer (Novagen).
RESULTS
Recent work in this laboratory has identified two elements, namely the AP-1 and RD sites, as required for collagenase-3 promoter activity in response to PTH in the rat osteoblastic osteosarcoma cell line UMR 106-01 (15) . We have also shown that there is an increased amount of c-Fos and c-Jun proteins binding to the AP-1 site in response to PTH, but there is no change in the abundance of Cbfa (AML) binding to the RD site. Three isoforms of Cbfa1 have been identified that differ in their N-terminal sequence (30) . To identify whether there is a change in the levels of Cbfa1 isomeric forms by PTH, total cellular lysates from control and PTH-treated UMR cells were isolated and used for Western blot analysis. Both control and PTH-treated lysates contained a major protein of ϳ45 kDa that was recognized by an affinity-purified antibody made against Cbfa1 (anti-human AML-3 raised against a C-terminal peptide) (Fig. 1A) . In addition, we have also found a minor protein of ϳ35 kDa. Since there was no change in the abundance of the Cbfa1 isoforms during PTH treatment, the possibility exists that either different Cbfa1 isoforms of the same mass are expressed or, more likely, that Cbfa1 is posttranslationally modified. The expression pattern of Cbfa1 transcripts in control and PTH-treated UMR cells was identified by Northern blot analysis using a mouse Cbfa1-specific riboprobe. This riboprobe hybridized to three transcripts (6.5, 5.4, and 3.2 kilobases) in either control or PTHtreated UMR cells (Fig. 1B) . There was no change in the level of Cbfa1 RNA in either control or PTH-treated conditions. The RNA loading and efficiency of transfer were verified by reprobing the blot with ␤-actin cDNA. That there was no change in the levels of Cbfa1 RNA or protein in UMR cells under either control conditions or after PTH treatment (Fig. 1, A and B) suggests that PTH regulates Cbfa1 posttranslationally.
Earlier, we showed that PTH phosphorylates CREB, resulting in activation of the c-fos promoter (31) . Recently, we also reported that the PTH-induced phosphorylation of CREB is mediated by the PKA pathway (32) . Identifying the PTH signaling pathway for collagenase-3 promoter activity would provide insight into a possible posttranslational modification of Cbfa1. Hence, to identify the signaling pathway involved for PTH-induced collagenase-3 promoter activity, we used PKA, PKC, and ERK pathway inhibitors. The collagenase-3 promoter construct (Ϫ148 C'ase-3) was transiently transfected into UMR cells. The cells were then pretreated with PD98059 (ERK pathway inhibitor) or GF109203X (PKC inhibitor) for 20 min, then treated with or without PTH (10 Ϫ8 M) for 24 h. Lysates were then assayed for CAT activity (Fig. 2) . The CAT activity was not affected by these inhibitors, suggesting that the ERK and PKC, signaling pathways are not involved in the PTH stimulation of collagenase-3 promoter activity. When we used H-89 (PKA inhibitor), PTH-induced collagenase-3 promoter activity was inhibited (Fig. 3A) . In addition, we have also transfected PKI, the heat-stable inhibitor of PKA (Fig. 3B) , and the result clearly indicated that PTH stimulation of collagenase-3 promoter activity was abrogated by PKA inhibition. Hence, PTHinduced collagenase-3 promoter activity is mediated by the PKA pathway.
To distinguish the primary effect of PKA on c-fos promoter activity from Cbfa1 transactivation, we utilized the heterologous Gal4 transcription factor system. A region of 135 amino acids within the proline-, serine-, threonine-rich domain of Cbfa1, C-terminal to the DNA binding domain (runt), called AD3, is required for transactivation (29) . Unlike AD1 and AD2, AD3 can function in a heterologous system (29) , and it contains consensus phosphorylation sites for PKA, PKC, casein kinase II, and ERK. Since the collagenase-3 promoter activity was ablated by inhibition of PKA, and not by PKC or ERK inhibitors, we concentrated on the role of PKA activity on Cbfa1 transactivation. To examine the role of PKA in the transactivation of Cbfa1, we generated Gal4 AD3 and the PKA site mutant Gal4 AD3 expression vectors. These constructs were transiently cotransfected into UMR cells with an expression construct coding for the PKA catalytic subunit as well as a luciferase reporter gene containing Gal4 binding sites (Fig. 4A) . The wild type AD3 construct demonstrated enhanced luciferase activity when the vector for PKA was cotransfected, indicating that the PKA site in the wild type AD3 construct is functional and mediates the AD3 transactivation. To determine the PTHstimulated AD3 transactivation, the wild type AD3 construct was transiently transfected into UMR cells and then treated with control or PTH (10 Ϫ8 M)-containing media (Fig. 4B) . The AD3 of Cbfa1 had enhanced luciferase activity when the cells were treated with PTH, whereas cotransfection with PKI, a dominant inhibitor of PKA, inhibited the PTH-induced activity. These results show that the transactivation of AD3 by PTH is mediated by the PKA signaling pathway. When the PKA site mutant AD3 construct was transfected into UMR cells, no PTH-induced luciferase activity was detected (Fig. 4C) . This further supports the previous data that the PTH-induced transactivation of AD3 in Cbfa1 is mediated by PKA.
To determine whether AD3 can be phosphorylated by PKA, the wild type and PKA site mutant AD3 of Cbfa1 were cloned into vectors enabling expression in E. coli as His-and S-tag fusion proteins. The purified AD3 proteins were subjected to in vitro phosphorylation by PKA (Fig. 5A) . The recombinant wild type AD3 was phosphorylated by PKA, whereas mutation of the PKA site abolished phosphorylation of AD3 by PKA. Autophosphorylation of PKA was also observed by incubating PKA in phosphorylation buffer without substrate (AD3). The purified recombinant AD3 proteins contain an S tag. Western blot analysis with horseradish peroxidase-conjugated anti-S-tag protein was used to verify that equal amounts of the wild type and PKA mutant AD3 were present in the phosphorylation reaction (Fig. 5B) . These results indicated that PKA can phosphorylate the wild type AD3, and this is mediated by the   FIG. 1. A, Western blot analysis of Cbfa1. Fifty g of total cellular lysate isolated from control and PTH-treated (2 h) UMR cells were used for Western blot analysis using Cbfa1 antibody (anti-human AML-3). The arrow indicates a major band (ϳ45 kDa) found in both control and PTH-treated lysates. B, Northern blot analysis of Cbfa1 mRNA abundance. One g of poly(A) ϩ mRNA isolated from control and PTH-treated (2 h) UMR cells was used for Northern blot analysis using a mousespecific Osf2/Cbfa1 riboprobe. The filter was stripped and reprobed with a ␤-actin cDNA probe to verify an equal amount of RNA loading and transfer. identified PKA site. Thus, the PKA phosphorylation site within AD3 is the likely site for PKA-mediated transactivation of Cbfa1.
DISCUSSION
Previous studies from our laboratory showed enhanced binding of c-Fos and c-Jun proteins at the AP-1 site upon treatment with PTH. However, there was no significant change in the level of Cbfa1 binding to the RD site (15) . By Western and Northern blot analyses, we show here that there is no change in the levels of Cbfa1 RNA or protein in UMR cells under either control condition or after PTH treatment (Fig. 1, A and B) . The presence of three Cbfa1 transcripts in the UMR cells (Fig. 1B) could be due to the difference in their N-terminal sequences or the alternative splicing, which leads to selective loss of exons. Several isoforms of Cbfa1 have been identified by differential promoter usage or differential splicing (30). Merriman et al. (19) report the presence of two transcripts in ROS 17/2.8. By Western blot, we found a minor protein of ϳ35 kDa in addition to the predominant ϳ45 kDa band showing that Cbfa1 antibody (anti-human AML-3 raised against a C-terminal peptide) will cross-react with other Cbfa1 isomeric forms having different N-terminal amino acid sequences (30) . Recently, investigation of the functional differences of the three Cbfa1 isoforms (26, 33, 34) has shown that all three isoforms are involved in the stimulatory action of osteoblast differentiation, but they exert different functions in the process of osteoblast differentiation (35) . In our studies, no change in the levels of Cbfa1 RNA or protein in UMR cells either in control or PTH-treated cells suggests posttranslational modification of Cbfa1 in response to PTH. It cannot be ruled out that different activities of isomeric forms of transcription factors generated by alternative splicing may result from different interaction with cofactors (36) . It is also possible that PTH regulates Groucho/TLE2, a repressor protein (29) , resulting in the alteration of Cbfa1 transactivation. The posttranscriptional regulation of Cbfa1 for TRI promoter activity in glucocorticoid-treated bone cells has also been ing media for 24 h and assayed for CAT activity. B, the collagenase-3 promoter construct was transiently cotransfected into UMR 106-01 with the indicated amounts of PKI, the heat-stable inhibitor of PKA catalytic subunit, followed by control or PTH (10 Ϫ8 M)-containing media for 24 h, and assayed for CAT activity. Background was defined as the activity of the promoterless, enhancerless vector, pSV0CAT. Data represent the mean Ϯ S.E. of three wells. Cm, chloramphenicol.
FIG. 4. Transactivation of Cbfa1 by PKA.
A, The Gal4 AD3 wild type (W) and PKA site mutant (M) constructs were transiently transfected into UMR cells with an expression vector for the PKA catalytic subunit as well as a reporter plasmid containing the luciferase gene driven by five copies of the Gal4 upstream activation sequence and the adenovirus E1b minimal promoter. The cells were incubated for 6 h and assayed for luciferase activity. B, the Gal4 AD3 wild type (W) construct alone or together with PKI (50 ng) and the reporter plasmid were transiently transfected into UMR cells and then treated with control or PTH (10 Ϫ8 M)-containing media for 6 h. Lysates were then assayed for luciferase activity. C, the Gal4 AD3 wild type (W) and PKA site mutant (M) constructs were transiently transfected into UMR cells with the reporter plasmid, then treated with control or PTH (10 Ϫ8 M)-containing media for 6 h and assayed for luciferase activity. Data represent the mean Ϯ S.E. of three wells. RLU, relative light units; dbd, DNA binding domain.
proposed (37) but does not appear to be a factor here since there are no changes in mRNA or protein for Cbfa1.
PTH binds to the PTH/PTH-related protein receptor on osteoblastic cells and generates multiple second messengers including cAMP (which activates PKA), diacylglycerol (which activates PKC), inositol trisphosphate, and increased levels of intracellular calcium (38, 39) . The transient transfection experiments of collagenase-3 promoter with PKA, PKC, and ERK inhibitors in UMR cells clearly indicate that PTH stimulation of collagenase-3 promoter activity is completely abrogated by PKA inhibition and not by inhibition of the other pathways. Other studies in our laboratory have shown that the ERK pathway inhibitor PD98059 inhibits ERKs (ERK1 and ERK2) at 50 M and the PKC pathway inhibitor GF109203X inhibits PKC at 1 M in UMR cells (data not shown). If PTH-induced collagenase-3 promoter activity is regulated through either the ERK or the PKC signaling pathway, then those inhibitors used at the concentrations in these studies should have inhibited the PTH effect. This is not the case. Many genes such as ␣1(I) collagen (40), plasminogen activator inhibitor-1 (41), leukemia inhibitory factor (3), sodium/proton exchanger NHE-1 isoform (42), and PTH/PTH-related protein receptor (43, 44) are regulated by PTH through the PKA-mediated pathway. PTH induction of prostaglandin G/H synthase-2 (5), interleukin-6 (45, 46) , and ICER (inducible cAMP early repressor) (47) in osteoblastic cells are also mediated by the PKA pathway. By individually expressing distinct, stably transfected cAMP-, serum-, and phorbol ester-inducible luciferase genes, it has been shown that PTH-induced cAMP/PKA signaling pathway plays a predominant role in UMR cells (48) .
Recently we also showed that PKA is the enzyme responsible for phosphorylating CREB in response to PTH and that PKA activity is required for PTH-induced c-fos expression (32) . Since PTH-induced collagenase-3 promoter activity is mediated by the PKA signaling pathway (Fig. 3) , the primary effect of PKAmediated CREB phosphorylation was distinguished from Cbfa1 transactivation by using the yeast Gal4 transcription factor system. The transient transfection studies with the wild type and the PKA mutant Gal4 AD3 constructs indicate that the transactivation of AD3 in Cbfa1 is dependent on the presence of the PKA consensus phosphorylation site and PTH induces the transactivation of AD3 through the PKA site (Fig. 4) . Thus, the PKA site in AD3 of Cbfa1 is necessary for PTHinduced collagenase-3 promoter activity. Since the assembly of transcriptional proteins has important implications for the accuracy and diversity of transcriptional regulation in vivo, it cannot be ruled out that all three activation domains of Cbfa1 may be required for full transcriptional activity in the context of native protein by directly or indirectly interacting with other transcription factors like the AP-1 factors to regulate PTHinduced collagenase-3 promoter activity.
It is well known that protein phosphorylation is one of the most important processes for cellular regulation and signal transduction in eukaryotic cells and phosphorylation of transcription factors often plays a key role in modulating DNA binding and/or functional activity. In vitro phosphorylation studies indicate that the wild type AD3 is a substrate for phosphorylation by PKA (Fig. 5) , suggesting that PTH-induced transactivation of Cbfa1 is mediated by PKA phosphorylation of AD3. Taken together (Figs. 4 and 5) , we propose that the mechanism by which PTH stimulates the rat collagenase-3 promoter is via phosphorylation and activation of Cbfa1 by PKA in addition to the enhanced level of c-Fos and c-Jun proteins. Since we did not observe increased binding of Cbfa1 to the RD site of collagenase-3 promoter in response to PTH by gel shift experiments (15) , it is likely that the phosphorylated Cbfa1 may not have increased DNA binding activity. Similarly, it has been shown that the Cbfa2 phosphorylated in response to cytokines is unchanged in DNA binding activity (49) . It is possible that the phosphorylation of Cbfa1 could lead to enhanced interaction with AP-1 factors either directly or indirectly for PTH-induced collagenase-3 promoter activity. In our laboratory, we have also used other osteoblastic cells to study the PTH effect on collagenase-3 expression. We have found that the effect of PTH on collagenase-3 mRNA expression in normal, differentiating osteoblasts and MC3T3 cells is only 2-3-fold (50) . 2 In ROS 17/2.8 cells, collagenase-3 is not induced in response to PTH, even though these cells are responsive to PTH in terms of production of cAMP. 3 Hence, it may be difficult to dissect the signaling pathway for PTH-induced collagenase-3 promoter activity in other osteoblastic cells.
In summary, we have found that the PKA site of AD3 in Cbfa1 appears to be physiologically important and involved in PTH action and could also be involved in prostaglandin E 2 action through the PKA pathway. Mutation of this site could possibly impair PTH-induced bone resorption, since this site is involved in PTH-induced collagenase-3 promoter activity. FIG. 5 . Phosphorylation of Cbfa1 by PKA. The purified recombinant wild type (W) and PKA mutant (M) AD3 of Cbfa1 were incubated with increasing concentrations of the catalytic subunit of PKA (0, 1, 2, and 4 units) for 15 min at 37°C. A control sample without substrate (AD3) but with PKA (4 units) was included. The reaction was stopped by the addition of SDS-PAGE sample buffer, and the samples were separated by SDS-PAGE and blotted onto polyvinylidene difluoride membrane. The membrane was first exposed to autoradiography (A) and then analyzed by Western blot (B) using horseradish peroxidase-conjugated anti-S-tag protein.
